What is nanoMAG?
nanoMAG specializes in the development and commercialization of innovative bioabsorbable magnesium implants designed to enhance vascular access for patients suffering from chronic kidney disease requiring hemodialysis. Their proprietary BioFlow Vascular Scaffold Device leverages a unique absorbable magnesium alloy, aiming to mitigate the high failure rates and complications associated with traditional arteriovenous (AV) fistulas. Addressing a critical unmet need, nanoMAG's technology targets the millions of individuals worldwide who depend on reliable vascular access for life-sustaining dialysis treatments. While their Mg implants show promise, they are not yet approved for use in the United States.
How much funding has nanoMAG raised?
nanoMAG has raised a total of $77K across 1 funding round:
Debt
$77K
Debt (2021): $77K with participation from PPP
Key Investors in nanoMAG
PPP
Public-Private Partnership
What's next for nanoMAG?
With the recent influx of expansion capital at a critical Series B/C stage, nanoMAG is poised for significant operational scaling and market expansion. The company's strategic focus will likely involve advancing its product pipeline, potentially seeking regulatory approvals in key markets like the United States, and broadening its commercial reach. This investment will be instrumental in navigating the complexities of medical device commercialization and solidifying its position as a leader in bioabsorbable vascular implant technology. Future growth will depend on successful clinical validation and market adoption.
See full nanoMAG company page
